
Shitanshu Uppal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6381427/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation. American Journal of Obstetrics and Gynecology, 2016, 214, 98.e1-98.e13.	1.3	124
2	Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. Journal of Clinical Oncology, 2020, 38, 1030-1040.	1.6	120
3	Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53. PLoS ONE, 2012, 7, e53178.	2.5	112
4	Frailty index predicts severe complications in gynecologic oncology patients. Gynecologic Oncology, 2015, 137, 98-101.	1.4	112
5	Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecologic Oncology, 2016, 143, 236-240.	1.4	97
6	Laparoendoscopic Single-Site Surgery in Gynecology: Review of Literature and Available Technology. Journal of Minimally Invasive Gynecology, 2011, 18, 12-23.	0.6	83
7	Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight, 2020, 5, .	5.0	74
8	Preoperative hypoalbuminemia is an independent predictor of poor perioperative outcomes in women undergoing open surgery for gynecologic malignancies. Gynecologic Oncology, 2013, 131, 416-422.	1.4	66
9	Resident participation in laparoscopic hysterectomy: impact of trainee involvement on operative times and surgical outcomes. American Journal of Obstetrics and Gynecology, 2014, 211, 484.e1-484.e7.	1.3	63
10	Predictors of 30-day readmission and impact of same-day discharge in laparoscopic hysterectomy. American Journal of Obstetrics and Gynecology, 2015, 213, 344.e1-344.e7.	1.3	59
11	Comparison of robotic and other minimally invasive routes of hysterectomy for benign indications. American Journal of Obstetrics and Gynecology, 2016, 215, 650.e1-650.e8.	1.3	56
12	The Effectiveness of Periodontal Disease Treatment During Pregnancy in Reducing the Risk of Experiencing Preterm Birth and Low Birth Weight. Journal of the American Dental Association, 2010, 141, 1423-1434.	1.5	45
13	Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Obstetrics and Gynecology, 2017, 129, 979-985.	2.4	44
14	Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer. Obstetrics and Gynecology, 2015, 126, 1198-1206.	2.4	42
15	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. Gynecologic Oncology, 2020, 158, 236-243.	1.4	42
16	Prophylactic Antibiotic Choice and Risk of Surgical Site Infection After Hysterectomy. Obstetrics and Gynecology, 2016, 127, 321-329.	2.4	41
17	Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012–2015). Gynecologic Oncology, 2019, 152, 133-138.	1.4	40
18	Minimally Invasive Staging Surgery in Women with Early-Stage Endometrial Cancer: Analysis of the National Cancer Data Base. Annals of Surgical Oncology, 2017, 24, 1677-1687.	1.5	32

#	Article	IF	CITATIONS
19	Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores. Gynecologic Oncology, 2019, 152, 106-111.	1.4	31
20	Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients. Gynecologic Oncology, 2012, 127, 631-637.	1.4	30
21	Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2020, 108, 620-634.	0.8	30
22	Resident Competency in Obstetric Anal Sphincter Laceration Repair. Obstetrics and Gynecology, 2010, 115, 305-309.	2.4	29
23	Association of Hospital Volume With Racial and Ethnic Disparities in Locally Advanced Cervical Cancer Treatment. Obstetrics and Gynecology, 2017, 129, 295-304.	2.4	29
24	Surgical site infection following hysterectomy: adjusted rankings in a regional collaborative. American Journal of Obstetrics and Gynecology, 2016, 214, 259.e1-259.e8.	1.3	27
25	Reducing surgical site infections after hysterectomy: metronidazole plus cefazolin compared with cephalosporinÂalone. American Journal of Obstetrics and Gynecology, 2017, 217, 187.e1-187.e11.	1.3	27
26	Panâ€cancer clinical and molecular analysis of racial disparities. Cancer, 2020, 126, 800-807.	4.1	25
27	Readmissions after major gynecologic oncology surgery. Gynecologic Oncology, 2016, 141, 287-292.	1.4	24
28	Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. BMC Cancer, 2018, 18, 172.	2.6	24
29	The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecologic Oncology, 2016, 143, 521-525.	1.4	23
30	Chlorhexidine-Alcohol Compared With Povidone-Iodine for Preoperative Topical Antisepsis for Abdominal Hysterectomy. Obstetrics and Gynecology, 2017, 130, 319-327.	2.4	20
31	Ongoing strategies and updates on pain management in gynecologic oncology patients. Gynecologic Oncology, 2018, 149, 410-419.	1.4	19
32	Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. Gynecologic Oncology, 2019, 154, 283-289.	1.4	19
33	Gynecologic radiation oncology patients report unmet needs regarding sexual health communication with providers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 495-502.	2.5	19
34	Trends in hospice discharge, documented inpatient palliative care services and inpatient mortality in ovarian carcinoma. Gynecologic Oncology, 2016, 143, 371-378.	1.4	18
35	Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer. Gynecologic Oncology, 2016, 142, 286-292.	1.4	18
36	Are perioperative bundles associated with reduced postoperative morbidity in women undergoing benign hysterectomy? Retrospective cohort analysis of 16,286 cases in Michigan. American Journal of Obstetrics and Gynecology, 2017, 216, 502.e1-502.e11.	1.3	18

#	Article	IF	CITATIONS
37	Modify or abandon: minimally invasive radical hysterectomy for early-stage cervical cancer. International Journal of Gynecological Cancer, 2019, 29, 843-844.	2.5	18
38	Safety and tolerability of chlorhexidine gluconate (2%) as a vaginal operative preparation in patients undergoing gynecologic surgery. American Journal of Infection Control, 2016, 44, 996-998.	2.3	17
39	Hospital Readmission as a Poor Measure of Quality in Ovarian Cancer Surgery. Obstetrics and Gynecology, 2018, 132, 126-136.	2.4	15
40	Trends and racial disparities in aggressive endâ€ofâ€life care for a national sample of women with ovarian cancer. Cancer, 2021, 127, 2229-2237.	4.1	15
41	An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab. Gynecologic Oncology Reports, 2021, 37, 100819.	0.6	14
42	Since surgery isn't getting any easier, why is reimbursement going down? An update from the SGO taskforce on coding and reimbursement. Gynecologic Oncology, 2017, 144, 235-237.	1.4	13
43	Preoperatively predicting non-home discharge after surgery for gynecologic malignancy. Gynecologic Oncology, 2019, 152, 293-297.	1.4	13
44	Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium. Obstetrics and Gynecology, 2015, 126, 815-822.	2.4	12
45	β-Lactam vs Non-β-Lactam Antibiotics and Surgical Site Infection in Colectomy Patients. Journal of the American College of Surgeons, 2019, 229, 487-496.e2.	0.5	12
46	A phase II clinical trial of metformin as a cancer stem cell targeting agent in stage IIc/III/IV ovarian, fallopian tube, and primary peritoneal cancer Journal of Clinical Oncology, 2017, 35, 5556-5556.	1.6	12
47	Discrepancies Created by Surgeon Self-Reported Operative Time and the Effects on Procedural Relative Value Units and Reimbursement. Obstetrics and Gynecology, 2021, 138, 182-188.	2.4	11
48	Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1175-1182.	4.9	10
49	Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery. Obstetrics and Gynecology, 2017, 130, 305-314.	2.4	10
50	Association of a Biweekly Research Workgroup With Enhanced Resident Research Productivity. Obstetrics and Gynecology, 2016, 128, 617-620.	2.4	9
51	Timing of and Reasons for Unplanned 30-Day Readmission After Hysterectomy for Benign Disease. Obstetrics and Gynecology, 2016, 128, 889-897.	2.4	9
52	A retrospective cohort study of hemostatic agent use during hysterectomy and risk of postâ€operative complications. International Journal of Gynecology and Obstetrics, 2017, 136, 232-237.	2.3	8
53	Implementation of a standardized voiding management protocol to reduce unnecessary re-catheterization - A quality improvement project. Gynecologic Oncology, 2020, 157, 487-493.	1.4	7
54	Improving Global Outcomes in Cervical Cancer: The Time Has Come for International Federation of Gynecology and Obstetrics Staging to Formally Incorporate Advanced Imaging. Journal of Global Oncology, 2018, 4, 1-6.	0.5	6

#	Article	IF	CITATIONS
55	Optimization of postoperative opioid prescriptions in gynecologic oncology: Striking a balance between opioid reduction and pain control. Gynecologic Oncology, 2021, 162, 756-762.	1.4	6
56	Thrombocytosis is Predictive of Postoperative Pulmonary Embolism in Patients With Gynecologic Cancer. International Journal of Gynecological Cancer, 2015, 25, 1096-1101.	2.5	5
57	Percutaneous image-guided pelvic procedures in women with gynecologic cancers: utilization, complications, and impact on patient management. Abdominal Radiology, 2016, 41, 2460-2465.	2.1	5
58	Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments. Gynecologic Oncology, 2018, 150, 106-111.	1.4	5
59	Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success. Gynecologic Oncology, 2021, 160, 271-278.	1.4	4
60	Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. Gynecologic Oncology, 2021, 162, 148-153.	1.4	4
61	Adherence to Hematologic Hold Parameters in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 849-853.	4.9	3
62	Physician Influence on Variation in Receipt of Aggressive End-of-Life Care Among Women Dying of Ovarian Cancer. JCO Oncology Practice, 2022, 18, e293-e303.	2.9	3
63	Development of a Preoperative Clinical Risk Assessment Tool for Postoperative Complications After Hysterectomy. Journal of Minimally Invasive Gynecology, 2022, 29, 401-408.e1.	0.6	3
64	Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proofâ€ofâ€concept study. American Journal of Reproductive Immunology, 2021, 86, e13469.	1.2	2
65	Novasure as a Mechanical Endometrial Preparation Agent in Large Uteri. Journal of the Society of Laparoendoscopic Surgeons, 2012, 16, 537-541.	1.1	1
66	Palliative Care Rotations in Obstetrics and Gynecology, Internal Medicine, and Family Medicine Residency Programs [141]. Obstetrics and Gynecology, 2017, 129, 96S-96S.	2.4	1
67	Dosimetric impact of interfractional organs at risk variation during high-dose rate interstitial brachytherapy for gynecologic malignancies. Medical Dosimetry, 2019, 44, 239-244.	0.9	1
68	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations During the COVID-19 Pandemic. Obstetrical and Gynecological Survey, 2021, 76, 88-90.	0.4	1
69	Updated funding to lethality measures for National Cancer Institute funding allocation (2007-2017). Gynecologic Oncology, 2021, 162, S322-S323.	1.4	1
70	Phase I trial of ribociclib (LEE-011) with platinum-based chemotherapy in recurrent platinum sensitive ovarian cancer. Gynecologic Oncology, 2021, 162, S69.	1.4	1
71	Preoperative Hypoalbuminemia Is an Independent Predictor of Poor Perioperative Outcomes in Women Undergoing Open Surgery for Gynecologic Malignancies. Obstetrical and Gynecological Survey, 2013, 68, 795-796.	0.4	0
72	Management and Outcomes for Elderly Women with High-Grade Endometrial Cancer. Gynecologic Oncology, 2015, 139, 587.	1.4	0

#	Article	IF	CITATIONS
73	Reply. American Journal of Obstetrics and Gynecology, 2015, 212, 688.	1.3	Ο
74	Reply. American Journal of Obstetrics and Gynecology, 2016, 215, 250-251.	1.3	0
75	Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Obstetrical and Gynecological Survey, 2017, 72, 537-538.	0.4	0
76	Comparison of Robotic and Other Minimally-Invasive Routes of Hysterectomy for Benign Indications. Obstetrical and Gynecological Survey, 2017, 72, 158-159.	0.4	0
77	Are Perioperative Bundles Associated With Reduced Postoperative Morbidity in Women Undergoing Benign Hysterectomy? Retrospective Cohort Analysis of 16,286 Cases in Michigan. Obstetrical and Gynecological Survey, 2017, 72, 273-274.	0.4	Ο
78	Difference in Efficacy among β-Lactam Antibiotics and the Role of Mechanical Bowel Preparation. Journal of the American College of Surgeons, 2020, 230, 169-170.	0.5	0
79	Cancer lethality: an important burden metric to consider for the allocation of clinical trial research funding from all sources. Gynecologic Oncology, 2021, 162, S47.	1.4	Ο
80	The state of K2R grant funding by cancer type from the National Cancer Institute. Gynecologic Oncology, 2021, 162, S306-S307.	1.4	0
81	Retrospective comparison of emergent versus scheduled peripartum hysterectomies: a single institution experience. Gynecologic Oncology, 2021, 162, S264.	1.4	Ο
82	Abstract AS11: Mining the circulating immune cell transcriptome for ovarian cancer-specific biomarkers: a proof of concept study. , 2015, , .		0
83	Implementation of strategies to increase genetic counseling referral rates for ovarian cancer patients Journal of Clinical Oncology, 2018, 36, 1590-1590.	1.6	0
84	Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma. Radiology Imaging Cancer, 2020, 2, e190086.	1.6	0
85	Abstract CT208: Feasibility, acceptability, and evaluation of a self-care app to enhance purposeful living among ovarian cancer patients (NCT04458168). Cancer Research, 2022, 82, CT208-CT208.	0.9	0